期刊
PHARMACOLOGICAL RESEARCH
卷 70, 期 1, 页码 139-146出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2013.01.006
关键词
3,3 '-Diindolymethane; BRCA1; Adriamycin; Cardiac fibrosis
资金
- National Science Fund for Distinguished Young Scholars [81025019]
- National Basic Research Program of China [2012CB517603]
- National Natural Science Foundation of China [31071232, 31170751, 51173076, 91129712, 81102489, 31271013]
- Chinese Ministry of Education [108059]
- PhD Programs Foundation of the Ministry of Education of China [20100091120020]
- National Undergraduate Innovation Program
- National Natural Science
The cardiotoxicity of adriamycin greatly limits its application in the treatment of cancer. Heart failure that is caused by adriamycin-treatment induced cardiac fibrosis is a major cause of death in patients who are treated with this medication. The severe oxidative stress that is induced by adriamycin is considered to be one of the primary mechanisms by which fibrogenesis of cardiac tissue occurs. In the present study, we demonstrate that 3,3'-diindolymethane (DIM) exhibits a significant anti-fibrosis effect on cardiac tissue in an animal model of adriamycin-induced cardiac fibrosis (AICF). Further studies demonstrated that DIM is able to dramatically up-regulate the expression of breast cancer type 1 susceptibility protein (BRCA1) in cardiac tissue and fibroblast, which subsequently activate the transcription factor Nuclear factor (erythroid-derived 2)-like 2 (Nrf2). The upregulation of this transcription factor resulted in the expression of several anti-oxidant genes in the cell. Because DIM is a safe food additive that has been used for decades, our findings suggest that there is a great potential for this chemical to be developed into a clinical medication for the treatment of adriamycin-induced heart failure during cancer therapy. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据